Lynne Werth
Family Medicine · Ontario, OHNPI 1811301112
Payments from drug & device makers
Across 112 payments — averaging $16.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$212
- Lilly USA, LLC$197
- Novartis$152
- Novo Nordisk$151
- Pfizer$123
- Exact Sciences$91
- plus $916 from 27 others
What the payments were for
- Food & beverage$1,842100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$1,842 in reported general payments places this provider in the 70th percentile of 3,983 family medicine providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 42 | $55,922 |
| JardianceEmpagliflozin | 41 | $55,169 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $30,967 |
| TrulicityDulaglutide | 13 | $27,594 |
| Spiriva RespimatTiotropium Bromide | 15 | $21,557 |
| EliquisApixaban | 16 | $20,912 |
| XareltoRivaroxaban | 11 | $12,337 |
| Spiriva HandihalerTiotropium Bromide | 11 | $12,121 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 16 | $10,127 |
| Incruse ElliptaUmeclidinium Bromide | 13 | $4,526 |
| DuleraMometasone/Formoterol | 11 | $3,836 |
| Atorvastatin Calcium | 341 | $2,106 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 87 | $2,081 |
| Risedronate Sodium | 13 | $1,911 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 16 | $1,821 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Spiriva Respimat | $17 | $76,72656 claims |
| Novo NordiskOzempic | $151 | $55,92242 claims |
| GSKTrelegy Ellipta, Incruse Ellipta | $45 | $35,49347 claims |
| Lilly USA, LLCTrulicity | $197 | $27,59413 claims |
| PfizerEliquis | $123 | $20,91216 claims |
| Johnson & JohnsonXarelto | $32 | $12,33711 claims |
| AstraZenecaBreztri Aerosphere | $42 | $10,12716 claims |
| MerckDulera | $30 | $3,83611 claims |
| AbbVieSynthroid | $212 | $56534 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Ontario
- Michael ButcherCincinnati$18.3M
- William RandallKettering$7.5M
- Paul NugentCincinnati$4.9M
- Steve ChoiDayton$4.8M
- Martin SchearDayton$2.2M
- Rajesh DavitCincinnati$2M
- Kwabena OtengSpringdale$2M
- Blaise GattoMoraine$1.8M
- Cathy GreiweColumbus$1.4M
- Brian BeesleyColumbus$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.